Overview
<cite index="2-2">Founded by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko Health announced the completion of its $700 million Series C funding round on July 15, 2026.</cite> <cite index="1-1">The round was led by Lightspeed Venture Partners and propels Neko Health to a valuation of nearly $7 billion.</cite> <cite index="4-10">The deal represents a roughly fourfold increase from the company's $1.7 billion valuation at its $260 million Series B in January 2025.</cite>
Investors and Syndicate
<cite index="2-3,2-4">The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD.</cite> <cite index="2-5,2-6">As part of the round, David Ofer of O.G. Venture Partners will join the Board of Directors, subject to regulatory approval.</cite> The syndicate also included a notable cohort of individual backers: <cite index="9-7">the funding round saw participation from Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Ari Emanuel, Claudia Schiffer and Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Tim Ferriss, and will.i.am.</cite>
Product and Technology
<cite index="10-7">At the heart of Neko's offering is the Neko Health Scan, a 60-minute, comprehensive, non-invasive, and radiation-free health assessment that captures millions of health data points, priced at £299 in the UK and 2,750 SEK in Sweden.</cite> <cite index="17-15,17-16">The company captures data across an individual's skin, heart, blood, and metabolic health, with proprietary sensors and blood analysis assessing skin health including moles and marks, biomarkers to identify pre-diabetes risk, blood abnormalities, and risk factors linked to metabolic syndrome, stroke, and heart attack.</cite>
<cite index="1-6">Unlike many health companies, Neko owns every single part of its tech stack, building its own hardware and software in Sweden.</cite> <cite index="9-24,9-25">Last month, Neko opened its latest clinic in Stockholm, centered on the next generation of Neko-engineered medical devices — Derma-2, Echo-2, and Spectrum-2 — upgraded to capture a greater volume and higher-fidelity health signals across skin, heart, and circulation, with increased automation.</cite> <cite index="6-7">The scan can also incorporate Apple Health data, which Neko says gives its medical clinicians real-world data to use in assessments.</cite>
Clinical Outcomes and Scale
<cite index="3-18">Since launching in 2023, over 350,000 people have registered for a Neko Health Scan, and 100,000 people have received one.</cite> <cite index="5-21">Neko Health said approximately 75% of members book and prepay for their next annual scan before leaving their appointment.</cite> On clinical outcomes, <cite index="9-9,9-10">three in four returning members with previously identified severe or life-threatening conditions were in good health or had their condition under control, and five of seven key biomarkers showed statistically significant improvement between Scan 1 and Scan 2.</cite>
<cite index="8-15">By September 2025, the company had scaled its annualized recurring revenue (ARR) to $21.9 million, driven by the rollout of its London and Manchester clinics and high customer retention.</cite>
U.S. Expansion and Competitive Context
<cite index="5-10">The company plans to use the new capital to launch clinics in New York and other U.S. cities, expand its operations in Europe, and continue investing in clinical research, proprietary hardware, software, and diagnostic technology.</cite> <cite index="15-16">The startup has already received U.S. Food and Drug Administration (FDA) clearance for several core products, an important regulatory milestone supporting this expansion effort.</cite>
<cite index="17-9,17-10">Elective, direct-to-consumer full-body scanning is a growing market, fueled by advances in artificial intelligence that make scans faster; the market was valued at $29.7 billion in 2025 and is projected to reach $47.2 billion by 2033, according to data from SNS Insider.</cite> <cite index="17-14">Neko Health does not use large medical imaging machines like MRIs for its scans, unlike competitors Prenuvo and Ezra, now owned by Function Health.</cite> <cite index="4-4">The $700 million raise is one of the largest health-tech funding rounds in Europe this year and signals that investor enthusiasm for AI applications in healthcare extends well beyond drug discovery and clinical trials into consumer-facing preventive care.</cite>